Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal
Cell Carcinoma. The purpose of this study is to determine whether there is an overall
survival (OS) benefit between subjects treated with AGS-003 in combination with standard
treatment versus subjects treated with standard treatment alone.